Key facts
- Notable investors include Tech Incubator Program for Startup, Seoul National University Technology Holdings, Hisstory Venture Investments, iAccel (Seongnam-si).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nbios
- ·The full record, as it builds
Funding rounds
No funding rounds for Nbios are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nbios
Developer of non-toxic anticancer drugs and treatments designed for autoimmune diseases using selective technology. The company offers various healthcare products through their well being food and drink diagnosis and imaging new drug development technology, providing the healthcare industry with a cure for cancer.
- Sector
- Healthcare
- HQ
- Gangneung, South Korea
- Founded
- 2020
- Website
- nbiostec.com/
- Ownership
- Privately Held (backing)
Nbios doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nbios shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nbios in its N-PORT filings yet. We sweep new filings monthly.